US 12,467,051 B2
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
Brian Bettencourt, Groton, MA (US); William Querbes, Boston, MA (US); Kevin Fitzgerald, Brookline, MA (US); Maria Frank-Kamenetsky, Brookline, MA (US); Stuart Milstein, Arlington, MA (US); and Svetlana Shulga Morskaya, Sudbury, MA (US)
Assigned to Alnylam Pharmaceuticals, Inc., Cambridge, MA (US)
Filed by Alnylam Pharmaceuticals, Inc., Cambridge, MA (US)
Filed on Oct. 17, 2023, as Appl. No. 18/380,695.
Application 18/380,695 is a continuation of application No. 17/531,913, filed on Nov. 22, 2021, granted, now 11,866,709.
Application 17/531,913 is a continuation of application No. 17/089,854, filed on Nov. 5, 2020, granted, now 11,332,743, issued on May 17, 2022.
Application 17/089,854 is a continuation of application No. 16/411,261, filed on May 14, 2019, granted, now 10,934,545, issued on Mar. 2, 2021.
Application 16/411,261 is a continuation of application No. 15/683,999, filed on Aug. 23, 2017, granted, now 10,337,010, issued on Jul. 2, 2019.
Application 15/683,999 is a continuation of application No. 15/068,912, filed on Mar. 14, 2016, granted, now 9,771,591, issued on Sep. 26, 2017.
Application 15/068,912 is a continuation of application No. 14/132,999, filed on Dec. 18, 2013, granted, now 9,322,018, issued on Apr. 26, 2016.
Application 14/132,999 is a continuation of application No. PCT/US2012/043378, filed on Jun. 20, 2012.
Claims priority of provisional application 61/638,288, filed on Apr. 25, 2012.
Claims priority of provisional application 61/499,620, filed on Jun. 21, 2011.
Prior Publication US 2024/0175030 A1, May 30, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/113 (2010.01); A61K 31/7105 (2006.01); A61K 31/713 (2006.01); C12Q 1/68 (2018.01)
CPC C12N 15/1136 (2013.01) [A61K 31/7105 (2013.01); A61K 31/713 (2013.01); C12N 15/113 (2013.01); C12N 2310/14 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/322 (2013.01); C12N 2310/3515 (2013.01)] 13 Claims
 
1. A double-stranded ribonucleic acid (dsRNA) for inhibiting expression of ANGPTL3, or a salt thereof,
wherein said dsRNA, or a salt thereof, comprises a sense strand and an antisense strand forming a double stranded region,
a) wherein the sense strand comprises at least 15 contiguous nucleotides from the nucleotide sequence 5′-ACAUAUAAACUACAAGUCAAA-3′ of SEQ ID NO:296 and the antisense strand comprises at least 15 contiguous nucleotides from the nucleotide sequence 5′-UUUGACUUGUAGUUUAUAUGUAG-3′ of SEQ ID NO: 481;
b) wherein the sense strand comprises at least 15 contiguous nucleotides from the nucleotide sequence 5′-CUAGAGAAGAUAUACUCCA-3′ of SEQ ID NO:24 and the antisense strand comprises at least 15 contiguous nucleotides from the nucleotide sequence 5′-UGGAGUAUAUCUUCUCUAG-3′ of SEQ ID NO:86;
c) wherein the sense strand comprises at least 15 contiguous nucleotides from the nucleotide sequence 5′-AAUCAAGAUUUGCUAUGUU-3′ of SEQ ID NO:23 and the antisense strand comprises at least 15 contiguous nucleotides from the nucleotide sequence 5′-AACAUAGCAAAUCUUGAUU-3′ of SEQ ID NO:85;
d) wherein the sense strand comprises at least 15 contiguous nucleotides from the nucleotide sequence 5′-CACUUGAACUCAACUCAAA-3′ of SEQ ID NO:21 and the antisense strand comprises at least 15 contiguous nucleotides from the nucleotide sequence 5′-UUUGAGUUGAGUUCAAGUG-3′ of SEQ ID NO:83; or
e) wherein the sense strand comprises at least 15 contiguous nucleotides from the nucleotide sequence 5′-UAUUUGAUCAGUCUUUUUA-3′ of SEQ ID NO: 16 and the antisense strand comprises at least 15 contiguous nucleotides from the nucleotide sequence 5′-UAAAAAGACUGAUCAAAUA-3′ of SEQ ID NO:78.